Citations 1
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
Stein, Eytan M. , Garcia‐Manero, Guillermo , Rizzieri, David A. , Tibes, Raoul , Jongen-Lavrenic, Mojca, Altman, Jessica K. , Thomson, Blythe, Blakemore, Stephen J. , Daigle, Scott R., Waters, Nigel J. , Suttle, A. Benjamin, Clawson, Alicia, Pollock, Roy M. , Krivtsov, Andrei V. , Armstrong, Scott A. , DiMartino, Jorge, Hedrick, Eric, Löwenberg, Bob , Tallman, Martin S. , Löwenberg, Bob , Berdeja, Jesús G. , Savona, Michael R.
Blood | May 3, 2018 | Volume: 131 | Issue: 24 | Pages: 2661-2669
Key Points Pinometostat demonstrates first evidence of DOT1L target inhibition and clinical responses in a subset of MLL-r advanced leukemia patients. The observed safety profile of pinometostat shows potential for exploration of combination therapies in leukemia.